BeOne Medicines Q2 Revenue Jumps 30% to $1.7B, Raises Full-Year Guidance

summarizeSummary

BeOne Medicines reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue and operating income guidance. BRUKINSA sales reached $1.2 billion, and non-GAAP diluted EPS was $3.84 per ADS.

check_boxKey Events · Earnings and Guidance · ONC

• Q2 Revenue Surges 30% to $1.7B

  Total revenue reached $1.705 billion, driven by BRUKINSA sales of $1.2 billion (up 31% YoY) and TEVIMBRA sales of $229 million (up 18% YoY).

• Full-Year Guidance Raised

  2026 total revenue guidance increased to $6.6–$6.8 billion (from $6.3–$6.5 billion); GAAP operating income guidance raised to $1.0–$1.1 billion (from $750–$850 million); non-GAAP operating income guidance raised to $1.7–$1.8 billion (from $1.45–$1.55 billion).

• Strong Profitability and Cash Flow

  GAAP diluted EPS of $2.05 per ADS; non-GAAP diluted EPS of $3.84 per ADS. Free cash flow was $435 million for the quarter, nearly double the prior-year period.

• Manufacturing Expansion Announced

  BeOne announced a $300 million expansion of its manufacturing and R&D center in Hopewell, New Jersey, to add small molecule capabilities.

auto_awesomeAnalysis · ONC · Life Sciences

A standout quarter for BeOne Medicines saw total revenue climb 30% year-over-year to $1.7 billion, propelled by the flagship BRUKINSA franchise, which grew 31% to $1.2 billion. Reflecting strong commercial execution and operating leverage, the company raised its full-year 2026 revenue guidance to $6.6–$6.8 billion and significantly boosted its operating income outlook. Non-GAAP diluted EPS of $3.84 per ADS handily beat expectations, while free cash flow surged to $435 million. The results underscore BeOne's transition to a sustainably profitable global oncology leader, though the stock's reaction will hinge on whether the raised guidance was already priced in after the recent run-up.